A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee
Completed · Phase 1 · Has a placebo group
Conditions studied: Knee Osteoarthritis
In brief
A study to assess safety, tolerability and clinical effects of single and repeat dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).
Key facts
- Study ID
- NCT04229225
- Run by
- Unity Biotechnology, Inc.
- People needed
- 35
- Starts
- 2020-01-23
- Expected to finish
- 2020-09-18
- Last updated by the study team
- 2020-10-19
Who can join
Age: 40 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Premier Medical Associates — The Villages, Florida, United States
- Drug Studies America — Marietta, Georgia, United States
- Sundance Clinical Research, LLC — St Louis, Missouri, United States
- Hassman Research Institute — Berlin, New Jersey, United States
- Rochester Clinical Research, Inc. — Rochester, New York, United States
- Arcis Healthcare LLC dba Lowcountry Orthopaedics and Sports Medicine — North Charleston, South Carolina, United States
- First Surgical Hospital — Bellaire, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.